Orexigen Therapeutics, Inc.: Chapter 11 case summary
ElevenFlo ·
Orexigen Therapeutics’ Chapter 11 case closed on June 30, 2026, after its liquidation plan became effective in 2019. The final decree Dkt. 1276 preserves the wind-down administrator’s authority to dispose of remaining assets and make final distributions; the final claims register Dkt. 1280 was filed on July 17, 2026.
Orexigen Therapeutics’ Chapter 11 case, filed on March 12, 2018, closed on June 30, 2026 under a final decree Dkt. 1276. The decree preserves the wind-down administrator’s authority to liquidate or abandon remaining assets, make final creditor distributions and pay necessary expenses. The final claims register Dkt. 1280 was filed on July 17, 2026.
Orexigen, the developer of the weight-management drug Contrave, entered bankruptcy after missing a $100 million net sales milestone under its secured notes indenture; its 2017 consolidated net sales were approximately $98 million, according to the first-day declaration Dkt. 3. Petition-date funded debt totaled $229,285,000 across three note instruments, calculated from the principal balances in the amended disclosure statement Dkt. 1002, including $165 million of secured notes and $64.285 million of unsecured notes.
The court confirmed the modified amended liquidation plan Dkt. 1113 on May 17, 2019, and the plan became effective on May 31, 2019, as reported in the effective-date notice Dkt. 1125. In its June 2026 final-decree motion Dkt. 1271, the administrator reported $22,166,846.90 in distributions, including $19,939,181.87 on secured claims and $2,098,328.23 on general unsecured claims. The motion reported $1,148,774.48 in reserves as of May 13, 2026, primarily for lender litigation expenses.
Sources
- Dkt. 3First Day DeclarationFiled Mar 12, 2018Mar 12, 2018
- Dkt. 1002Disclosure Statement for Debtor's Amended Plan of Liquidation (Filed by Orexigen Therapeutics, Inc.)Filed Mar 29, 2019Mar 29, 2019
- Dkt. 1113Findings of Fact, Conclusion of Law, and Order Confirming Debtor's Modified Amended Plan of LiquidationFiled May 17, 2019May 17, 2019
- Dkt. 1125Notice of (I) Effective Date of Debtor's Modified Amended Plan of Liquidation and (II) Bar Dates for Certain Claims (Filed by Orexigen Therapeutics, Inc.)Filed May 31, 2019May 31, 2019
- Dkt. 1271Motion for Final Decree and Case ClosingFiled Jun 11, 2026Jun 11, 2026
- Dkt. 1276Order Closing Chapter 11 CaseFiled Jun 30, 2026Jun 30, 2026
- Dkt. 1280Final Claims RegistersFiled Jul 17, 2026Jul 17, 2026